Early Experience of Vascular Endothelial Growth Factor (VEGF) Inhibitor in COVID-19 ARDS
Excerpt
The current severe acute respiratory syn-drome-corona-virus-2 (SARS-CoV-2) has spread like wildfire and engulfed the entire world in its wake [...]
Share and Cite
Marwah, V.; Choudhary, R.; Kumar, T.A.; Peter, D. Early Experience of Vascular Endothelial Growth Factor (VEGF) Inhibitor in COVID-19 ARDS. Adv. Respir. Med. 2021, 89, 618-620. https://doi.org/10.5603/ARM.a2021.0104
Marwah V, Choudhary R, Kumar TA, Peter D. Early Experience of Vascular Endothelial Growth Factor (VEGF) Inhibitor in COVID-19 ARDS. Advances in Respiratory Medicine. 2021; 89(6):618-620. https://doi.org/10.5603/ARM.a2021.0104
Chicago/Turabian StyleMarwah, Vikas, Robin Choudhary, Tentu Ajai Kumar, and Deepu Peter. 2021. "Early Experience of Vascular Endothelial Growth Factor (VEGF) Inhibitor in COVID-19 ARDS" Advances in Respiratory Medicine 89, no. 6: 618-620. https://doi.org/10.5603/ARM.a2021.0104